

( (S (NP-TMP (NP One day)
	     (SBAR-TMP after
		       (S (NP-SBJ Delmed Inc.)
			  (VP (VP made
				  (NP top management changes))
			      and
			      (VP disclosed
				  (NP (NP the end)
				      (PP of
					  (NP an important business tie))))))))
     ,
     (S (NP-SBJ its stock)
        (VP did n't
            (VP trade)))
     and
     (S (NP-SBJ the company)
        (VP forecast
            (NP (NP a `` significant '' drop)
		(NP-TMP next year)
		(PP in
		    (NP (NP sales)
			(PP of
			    (NP its core product)))))))
     .))
( (S-3 (NP-SBJ That disclosure)
       (VP came
	   (PRN ,
		(S (NP-SBJ a Delmed spokeswoman)
		   (VP said
		       (SBAR 0
			     (S *T*-3))))
		,)
	   (SBAR-TMP after
		     (S (NP-SBJ the American Stock Exchange)
			(VP alerted
			    (NP the company)
			    (SBAR that
				  (S (NP-SBJ trading)
				     (VP would n't
					 (VP resume
					     (PP-LOC in
						     (NP its stock))
					     (SBAR-TMP until
						       (S (NP-SBJ-2 (NP additional information)
								    (PP about
									(NP developments)))
							  (VP was
							      (VP provided
								  (NP *-2)))))))))))))
       .))
( (S (PP In
         (NP (NP addition)
             (PP to
                 (NP the forecast))))
     ,
     (NP-SBJ the company)
     (ADVP also)
     (VP said
         (SBAR 0
               (S (NP-SBJ it)
                  (VP is
                      (VP examining
                          (NP (NP potential cost cuts)
                              and
                              (NP (NP reductions)
                                  (PP-LOC in
					  (NP overhead)))))))))
     .))
( (S (NP-SBJ The spokeswoman)
     (VP said
         (SBAR 0
               (S (NP-SBJ the exchange)
                  (VP would
                      (VP resume
                          (NP (NP trading)
                              (PP of
                                  (NP Delmed stock)))
			  (NP-TMP today))))))
     .))
( (S (NP-SBJ (NP Delmed)
             ,
             (SBAR (WHNP-1 which)
                   (S (NP-SBJ *T*-1)
                      (VP makes and sells
                          (NP (NP peritoneal dialysis products)
                              (VP used
                                  (NP *)
                                  (PP-LOC-CLR in
					      (S-NOM (NP-SBJ *)
						     (VP treating
							 (NP kidney disease)))))))))
             ,)
     (PP-TMP on
	     (NP Tuesday))
     (VP announced
         (NP (NP the resignations)
             (PP (PP of
                     (NP (NP Robert S. Ehrlich)
                         ,
                         (NP (NP chairman)
			     ,
			     (NP president)
			     and
			     (NP chief executive officer))
                         ,))
                 and
                 (PP of
                     (NP (NP Leslie I. Shapiro)
                         ,
                         (NP (NP chief operating officer)
                             and
                             (NP chief financial officer)))))))
     .))
( (S (NP-SBJ-1 They)
     (VP were
         (VP succeeded
             (NP *-1)
             (PP by
                 (NP-LGS (NP executives)
			 (PP of
			     (NP (NP Fresenius USA Inc.)
				 and
				 (NP (NP its parent)
				     ,
				     (NP Fresenius AG)
				     ,
				     (SBAR (WHNP-2 which)
					   (S (NP-SBJ *T*-2)
					      (VP owns
						  (NP (NP (QP about 45) %)
						      (PP of
							  (NP Delmed)))))))))))))
     .))
( (S (PP-TMP At
	     (NP the same time))
     ,
     (NP-SBJ the
             (NAC-LOC New Brunswick
		      ,
		      N.J.
		      ,)
             company)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP negotiations)
                          (PP about
                              (NP (NP pricing)
                                  and
                                  (NP (NP volumes)
                                      (PP of
                                          (NP product)))))
			  (PP *ICH*-1))
                  (VP had
                      (VP collapsed
                          (PP-1 between
				(NP (NP it)
				    and
				    (NP (NP (NP its exclusive distributor)
					    (PP-LOC in
						    (NP the U.S.)))
					,
					(NP National Medical Care Inc)))))))))
     .))
( (S (PP-TMP Following
	     (NP (NP that announcement)
		 (NP-TMP Tuesday)))
     ,
     (ADVP however)
     ,
     (NP-SBJ-1 company officials)
     (VP were
	 (ADJP-PRD unavailable
		   (S (NP-SBJ *-1)
		      (VP to
			  (VP elaborate)))))
     .))
( (S (NP-TMP Yesterday)
     ,
     (NP-SBJ the spokeswoman)
     (VP said
         (SBAR 0
               (S (NP-SBJ (NP sales)
                          (PP of
                              (NP Delmed products))
                          (PP through
                              (NP (NP the exclusive arrangement)
                                  (PP with
                                      (NP National Medical)))))
                  (VP accounted
                      (PP-CLR for
			      (NP (NP 87 %)
				  (PP of
				      (NP (NP (NP Delmed 's)
					      1988 sales)
					  (PP of
					      (NP (QP $ 21.1 million) *U*))))))))))
     .))
( (S (S-TPC-2 (NP-SBJ The current distribution arrangement)
	      (VP ends
		  (PP-TMP-CLR in
			      (NP March 1990))
		  ,
		  (SBAR-ADV although
			    (S (NP-SBJ Delmed)
			       (VP said
				   (SBAR 0
					 (S (NP-SBJ-1 it)
					    (VP will
						(VP continue
						    (S (NP-SBJ *-1)
						       (VP to
							   (VP provide
							       (NP (NP some supplies)
								   (PP of
								       (NP the peritoneal dialysis products)))
							       (PP-DTV to
								       (NP National Medical))))))))))))))
     ,
     (NP-SBJ the spokeswoman)
     (VP said
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (S-TPC-1 (ADVP Nonetheless)
	      , ``
	      (NP-SBJ Delmed)
	      (ADVP-TMP currently)
	      (VP expects
		  (SBAR that
			(S (NP-SBJ 1990 sales)
			   ...
			   (VP will
			       (VP be
				   (PP-PRD significantly below 
					   (NP their 1989 level))))))))
     , ''
     (NP-SBJ the company)
     (VP said
	 (SBAR 0
	       (S *T*-1))
	 (PP-LOC in
		 (NP a statement)))
     .))
( (S (NP-SBJ Delmed)
     (VP said
         (NP-TMP yesterday)
         (SBAR (SBAR that
                     (S (NP-SBJ-1 Fresenius USA)
                        (VP would
                            (VP begin
                                (S (NP-SBJ *-1)
                                   (VP distributing
                                       (NP the product)))))))
               and
               (SBAR that
                     (S (NP-SBJ the company)
                        (VP is
                            (VP investigating
                                (NP other possible distribution channels)))))))
     .))
( (S (S-TPC-2 (PP In
		  (NP any case))
	      ,
	      (NP-SBJ-1 (NP supplies)
			(PP to
			    (NP patients)))
	      (VP wo n't
		  (VP be
		      (VP interrupted
			  (NP *-1)))))
     ,
     (NP-SBJ the company)
     (VP added
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (NP-SBJ (NP Fresenius)
             ,
             (NP a (ADJP West German) pharmaceutical concern)
             ,)
     (VP has
         (VP been
             (VP discussing
                 (NP (NP a transaction)
                     (SBAR (WHPP-1 in
				   (WHNP which))
                           (S (NP-SBJ-2 it)
                              (VP would
                                  (VP buy
                                      (NP Delmed stock)
                                      (PP-CLR for
					      (NP cash))
				      (PP-LOC *T*-1)
				      (S-PRP (NP-SBJ *-2)
					     (VP to
						 (VP bring
						     (NP its beneficial ownership)
						     (PP-DIR to
							     (NP (QP between 70 % and 80 %) *U*)))))))))))))
     .))
( (S (NP-SBJ The transaction)
     (ADVP also)
     (VP would
         (VP combine
             (NP (NP Fresenius USA)
                 and
                 (NP Delmed))))
     .))
( (S (S-TPC-1 But
	      (NP-SBJ-3 the plan)
	      (ADVP-TMP now)
	      (VP is
		  (VP being
		      ``
		      (VP reformulated
			  (NP *-3)))))
     ,
     ''
     (NP-SBJ-4 Delmed)
     (VP said
	 (S *T*-1)
	 ,
	 (S-ADV (NP-SBJ-2 *-4)
		(VP declining
		    (S (NP-SBJ *-2)
		       (VP to
			   (VP provide
			       (NP (NP most)
				   (PP of
				       (NP (NP the new terms)
					   (PP of
					       (NP the combination)))))))))))
     .))
( (SINV (VP Said
	    (S *ICH*-1))
	(NP-SBJ the spokeswoman)
	:
	``
	(S-1 (NP-SBJ The whole structure)
	     (VP has
		 (VP changed)))
	.))
( (S (NP-SBJ (NP The value)
             (PP of
                 (NP the company)))
     (VP has
         (VP changed))
     . ''))
( (S (NP-SBJ Delmed)
     (VP did
         (VP say
             (SBAR that
                   (S (NP-SBJ the proposal)
                      (ADVP still)
                      (VP would
                          (VP infuse
                              (NP cash)
                              (PP-CLR into
				      (NP Delmed))
                              (PRN but
				   (NP (NP less)
				       (PP than
					   (NP (NP the (QP $ 10 million) *U*)
					       (VP (ADVP-TMP originally)
						   expected
						   (NP *))))))))))))
     .))
( (S (NP-SBJ Delmed)
     (ADVP also)
     (VP would
         (VP receive
             (NP (NP the North American rights)
		 (PP to
		     (NP certain Fresenius AG products)))))
     .))
( (S-1 (NP-SBJ (NP Another option)
	       (PP for
		   (NP Delmed)))
       (PRN ,
	    (S (NP-SBJ the company)
	       (VP said
		   (SBAR 0
			 (S *T*-1))))
	    ,)
       (VP is
	   (SBAR-PRD that
		     (S (NP-SBJ it)
			(VP could
			    (VP sell
				(NP (NP its plant)
				    (PP-LOC in
					    (NP (NP Ogden)
						,
						(NP Utah)))))))))
       .))
( (S (NP-SBJ It)
     (VP added
         (SBAR that
               (S (NP-SBJ (NP no discussions)
                          (PP about
                              (NP such a sale)))
                  (VP are
                      (PP-PRD under
			      (NP way))))))
     .))
